Laura A.
- Country
- Finland
- Department
- Research
Research Overview
- Phase 2a Study of Oral SUN-627 for Safety, Tolerability, PK/PD, and CNS Neuroinflammation in Non‑Active Progressive Multiple Sclerosis (SPMS/PPMS)
- Evaluation of Istradefylline for Reducing Microglial Activation in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety Evaluation of Obexelimab in Relapsing Multiple Sclerosis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 2 of 26 partner sites.
Specializations
Multiple Sclerosis Research
This investigator specializes in advancing treatment approaches for various forms of multiple sclerosis, with particular emphasis on both progressive MS and relapsing multiple sclerosis.
- Progressive MS Management
- Relapsing MS Treatment
- CNS Inflammation Studies
The research focus includes investigating novel therapeutic interventions for managing MS progression and inflammation.
Neuroimaging Expertise
Demonstrates significant expertise in advanced neuroimaging techniques, particularly PET imaging and MRI diagnostics for neurological conditions.
- TSPO-PET Imaging
- Brain Lesion Analysis
- Microglial Activation Assessment
Utilizes sophisticated imaging protocols to evaluate treatment efficacy and disease progression in the central nervous system.
Therapeutic Innovation
Investigates novel therapeutic compounds targeting neuroinflammation and immune system modulation in multiple sclerosis.
- Anti-inflammatory Approaches
- Microglial Cell Modulation
- White Matter Assessment
Focuses on evaluating innovative treatments to address both inflammatory and neurodegenerative aspects of MS.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.